Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Conditions: Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Gastric Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Malignant Solid Neoplasm Interventions...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Trastuzumab+pyrotinib+taxene Sponsors: Huihua Xiong Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer Interventions: Drug: Trastuzumab emtansine; Drug: Pertuzumab Injection; Drug: Docetaxel; Drug: Tamoxifen; Drug: Letrozole; Drug: Goserelin Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
Conditions: Cardiotoxicity; Breast Cancer; Treatment Side Effects Interventions: Diagnostic Test: Plasma NT-proBNP Sponsors: Vastra Gotaland Region Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Conditions: HER2-positive Breast Cancer Interventions: Diagnostic Test: GeoMx data analysis with clinical outcome Sponsors: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Anlotinib; Drug: Trastuzumab deruxtecan Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Conditions: Advanced Breast Cancer; Metastatic Breast Cancer Interventions: Drug: Hydroxychloroquine; Drug: Sacituzumab Govitecan; Drug: Trastuzumab Deruxtecan Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Conditions: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors; HER2 Amplification; Colorectal Cancer Interventions: Drug: ELVN-002; Drug: Trastuzumab; Drug: 5-Fluorouracil; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Eribulin; Drug: paclitaxel; Drug: Leucovorin Sponsors: Enliven Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Conditions: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma Interventions: Drug: Zongertinib; Drug: Trastuzumab deruxtecan; Drug: Trastuzumab emtansine Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: DP303c; Drug: trastuzumab emtansine Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Conditions: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Other: Electronic Health Record Review; Drug: Enfortumab Vedotin; Other: Immunohistochemistry Staining Method; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Biological: Sacituzumab Govitecan; Biological: Trastuzumab Deruxtecan Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
Conditions: HER2-positive Metastatic Breast Cancer; Oligometastatic Disease Interventions: Drug: Trastuzumab emtansine Sponsors: N.N. Petrov National Medical Research Center of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Conditions: HER2-positive Metastatic Breast Cancer; First-line Treatment Interventions: Drug: disitamab vedotin; Drug: Pyrotinib; Drug: trastuzumab; Drug: Pertuzumab; Drug: taxane drug Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Dalcilib+letrozole+HP treatment group Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors
Conditions: Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) Interventions: Drug: Trastuzumab deruxtecan Sponsors: AstraZeneca; Daiichi Sankyo Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
